Home › Cancer (all types) › NCT07524218

Effect of Meal Timing During Adjuvant Treatment for Cancer

Effect of Meal Timing During Adjuvant Treatment for Cancer: A Randomized Clinical Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Age ≥18 years (no upper age limit)
* Any sex or gender
* Histologically or cytologically confirmed solid tumor treated with curative-intent surgical resection and planned initiation of systemic adjuvant therapy (chemotherapy, targeted therapy, immunotherapy, and/or radiation per standard of care)
* BMI ≥18.5 kg/m2
* Willing and able to adhere to the assessments, visit schedules, prohibitions, and restrictions

Exclusion Criteria:

* No plan for systemic adjuvant therapy after surgery
* Strictly adhering to a \<10-hour eating window on most days
* Regular overnight shift work (≥1 night shift per week)
* Dependent on parenteral or enteral nutrition
* Pregnant or breastfeeding
* Active second malignancy requiring systemic therapy (exceptions: non-melanoma skin cancers or in situ cervical cancers adequately treated)
* Severe psychiatric, cognitive, or social conditions that would interfere with adherence to study procedures

About the study

The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response, patient well-being and long-term metabolic health. In alignment with these priorities, we propose to focus on patients with histologically or cytologically confirmed solid tumors treated with curative-intent surgical resection and planned initiation of systemic adjuvant therapy (chemotherapy, targeted therapy, immunotherapy, and/or radiation per standard of care).

A promising strategy for improving the efficacy of anticancer treatments and reducing associated toxicities involves combining treatment with fasting regimens. In pre-clinical and clinical studies, various forms of fasting have been shown to induce tumor regression and improve long-term survival. According to the differential stress sensitization theory, fasting is thought to sensitize tumor cells to the cytotoxic effects of chemotherapy and radiation, while protecting healthy cells by increasing stress resistance. While healthy cells slow their growth and become more stress resistant in response to fasting, cancer cells cannot survive in nutrient-deficient environments; although the underlying mechanisms are not fully understood. However, extended water-only fasting can be challenging for patients and poses undue health risks. Intermittent fasting, and specifically time-restricted eating (TRE), may offer a viable alternative. TRE involves eating within a shorter window (e.g., 8 hours) and fasting for the remainder of the day but involves no other dietary restrictions. Because of its simplicity, TRE may be more sustainable than other fasting regimens. TRE also improves several cardio-metabolic endpoints, including insulin sensitivity, which may also be beneficial during anticancer treatments.

What is being tested

• Time-restricted eating (behavioral)
• Questionnaire Administration (other)
• Biospecimen Collection (procedure)
• Health coaching (behavioral)

Sponsor: Fred Hutchinson Cancer Center · Participants: 50 · Started: Aug 12, 2026

Contact the study team

• Jane Figueiredo, PhD · Phone: (310) 423-2746

Official record on ClinicalTrials.gov — NCT07524218

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.